Cat. No.: HY-N6028

Darutoside

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Darutoside is an orally effective diterpene compound with significant anti-inflammatory, analgesic, wound healing promotion, and immunomodulatory activities. Darutoside reduces edema and pain responses by inhibiting the expression of COX-2 and the migration of inflammatory cells. It regulates macrophage polarization towards the M2 type by inhibiting the NF-κB pathway, alleviating inflammation and promoting wound healing. Through multi-target regulation of metabolic networks, Darutoside significantly alleviates acute gouty arthritis.

For research use only. We do not sell to patients.

Purity: 99.89%
CAS No.: 59219-65-7
Formula: C₂₆H₄₄O₈
Molecular Weight:484.62

Storage:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Darutoside Chemical Structure

CAS No.: 59219-65-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]^[2]^[3]

COX-2

NF-κB

IL-1β

IL-8

IL-10

All COX Isoforms :

All NF-κB Isoforms :

All Interleukin Related Isoforms :

All TNF Receptor Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
MDA-MB-231	IC₅₀	>25 μM Compound: 6	Inhibition of EGF-induced invasion of human MDA-MB-231 cells by MTT assay Inhibition of EGF-induced invasion of human MDA-MB-231 cells by MTT assay	[PMID: 28302401]
RAW264.7	IC₅₀	>100 μM Compound: 6	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 30 mins followed by LPS challenge measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 30 mins followed by LPS challenge measured after 24 hrs by Griess assay	[PMID: 28302401]

In Vitro

Darutoside (0.1-1 mg/mL, 12 h) significantly inhibits the migration of RAW264.7 macrophages induced by LPS (HY-D1056)^[1].
Darutoside (0.1-10 μM, 24 h) inhibits the M1-type macrophage polarization by suppressing the NF-κB signaling pathway (reducing the levels of p-IkK, p-IkB, and p-p65) ^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Darutoside (0.2-2 mg/kg, local topical application, once a day for a total of 5 days) significantly reduces ear and paw edema in mice and decreases the number of convulsions induced by Acetic acid (HY-Y0319)¹.
Darutoside (10-100 μM, local topical application, once daily for a total of 7 days) inhibits local inflammatory responses and significantly promotes wound healing in mouse skin^[2].
Darutoside (40 mg/mL, p.o., 2 h before modeling, 6 h and 22 h after modeling for 3 doses) significantly alleviates acute gouty arthritis in rats by inhibiting inflammatory cell infiltration and release, promoting blood circulation and improving immunity^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mouse ear swelling model, mouse paw swelling model and mouse writhing test established in young female Kunming mice with 8 weeks (18-22 g)^[1]
Dosage:

0.2 and 2 mg/kg
Administration:

Local topical application, once daily for 5 days
Result:

Significantly reduced earlobe edema at 2 mg/kg.
Significantly alleviated paw edema induced by CFA (HY-153808), increased pain threshold, and reduced inflammatory cell infiltration.
Significantly reduce the number of convulsions induced by Acetic acid.

Animal Model:

Full-thickness skin defect model established in 7-week-old male C57/BL6 mice^[2]
Dosage:

10, 50, 100 μM (based on 2% Methylcellulose (HY-125861) gel)
Administration:

Local topical application, once daily for 7 days
Result:

Showed the most significant healing effect at 50 μM, with a significant increase in the wound healing rate.
Accelerated the migration and growth of epithelial cells at the wound edge.
Significantly reduced the expressions of Inosl, Il1b, Tnfa and Il6 in the wound tissue, and increased the expressions of M2 macrophage markers Mrc1, Tgfb and Il10.

Animal Model:

Acute gouty arthritis model established in male Wistar rats (8 weeks old, weighing 150 g)^[3]
Dosage:

40 mg/mL
Administration:

Oral administration (p.o.), 2 h before modeling, 6 h and 22 h after modeling for 3 doses
Result:

Significantly reduced the volume and thickness of the ankle joint.
Reduced the levels of serum IL-8, TNF-α, IL-1β, NF-κB and uric acid.
Significantly increased the level of the anti-inflammatory factor IL-10.

Chemical Information

CAS No. 59219-65-7
Appearance Solid
Molecular Weight 484.62
Formula C₂₆H₄₄O₈
Color White to light yellow
SMILES

C[C@]12[C@@]3([H])C(CC[C@]1([H])C(C)([C@H](O[C@]4([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)CO)CC2)C)=C[C@]([C@@H](O)CO)(C)CC3
Structure Classification
- Terpenoids
- Diterpenoids
Initial Source
- Plants
- Compositae
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (1)

All

Sort by:

Journal Impact Factor

Mol Immunol

Darutoside promotes skin wound healing via regulating macrophage polarization. [Abstract]

2025 Mar 25:181:129-138. PMID: 40138783

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (206.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0635 mL

10.3174 mL

20.6347 mL

5 mM

0.4127 mL

2.0635 mL

4.1269 mL

10 mM

0.2063 mL

1.0317 mL

2.0635 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Li YS, et al. Kirenol, darutoside and hesperidin contribute to the anti-inflammatory and analgesic activities of Siegesbeckia pubescens makino by inhibiting COX-2 expression and inflammatory cell infiltration. J Ethnopharmacol. 2021 Mar 25;268:113547. [Content Brief]

[2]. Gao L, et al. Darutoside promotes skin wound healing via regulating macrophage polarization. Mol Immunol. 2025 May;181:129-138. [Content Brief]

[3]. Wang J, et al. Revealing the pharmacological effect and mechanism of darutoside on gouty arthritis by liquid chromatography/mass spectrometry and metabolomics. Front Mol Biosci. 2022 Aug 24;9:942303. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0635 mL	10.3174 mL	20.6347 mL	51.5868 mL
	5 mM	0.4127 mL	2.0635 mL	4.1269 mL	10.3174 mL
	10 mM	0.2063 mL	1.0317 mL	2.0635 mL	5.1587 mL
	15 mM	0.1376 mL	0.6878 mL	1.3756 mL	3.4391 mL
	20 mM	0.1032 mL	0.5159 mL	1.0317 mL	2.5793 mL
	25 mM	0.0825 mL	0.4127 mL	0.8254 mL	2.0635 mL
	30 mM	0.0688 mL	0.3439 mL	0.6878 mL	1.7196 mL
	40 mM	0.0516 mL	0.2579 mL	0.5159 mL	1.2897 mL
	50 mM	0.0413 mL	0.2063 mL	0.4127 mL	1.0317 mL
	60 mM	0.0344 mL	0.1720 mL	0.3439 mL	0.8598 mL
	80 mM	0.0258 mL	0.1290 mL	0.2579 mL	0.6448 mL
	100 mM	0.0206 mL	0.1032 mL	0.2063 mL	0.5159 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Darutoside

Bioactive Compound Library Max

Bioactive Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Terpenoids Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Macrophage Related Compound Library

Multi-Target Compound Library

Radioprotector Library

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Darutoside

All COX Isoforms

All NF-κB Isoforms

All Interleukin Related Isoforms

All TNF Receptor Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Darutoside Related Classifications

HY-N6028 Related Classifications